<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04860947</url>
  </required_header>
  <id_info>
    <org_study_id>CIVI/2018/ET-01</org_study_id>
    <nct_id>NCT04860947</nct_id>
  </id_info>
  <brief_title>Assessment of sNfL Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients</brief_title>
  <acronym>NFL OCT</acronym>
  <official_title>Assessment of Serum Neurofilament-light Chain (NfL) Levels, Atrophy of the Macula Ganglion Cell Complex (GCC) by Optical Coherence Tomography (OCT) and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in Multiple Sclerosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Recherches en Biothérapie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that serum neurofilament-light chain (NfL) levels at baseline&#xD;
      and decrease of the macular ganglion cell complex (GCC) thickness at one year vs. baseline&#xD;
      are as good as progression of whole brain atrophy at one year vs. baseline to predict later&#xD;
      evolution of neurological disability in multiple sclerosis patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2019</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum Neurofilament Light Chain serum levels since baseline</measure>
    <time_frame>Baseline; 1 year</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Ganglion Cell Complex thickness since baseline</measure>
    <time_frame>Baseline; 1 year</time_frame>
    <description>Measured by Optical Coherence Tomography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in whole brain volume since baseline</measure>
    <time_frame>Baseline; 1 year</time_frame>
    <description>Assessed by MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expanded Disability Status Scale</measure>
    <time_frame>Baseline</time_frame>
    <description>Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expanded Disability Status Scale</measure>
    <time_frame>3 years</time_frame>
    <description>Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whole brain volume</measure>
    <time_frame>Inclusion</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole brain volume</measure>
    <time_frame>6 Months</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole brain volume</measure>
    <time_frame>1 Year</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole brain volume</measure>
    <time_frame>2 years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole brain volume</measure>
    <time_frame>3 Years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole brain volume</measure>
    <time_frame>4 Years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole brain volume</measure>
    <time_frame>5 years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole brain volume</measure>
    <time_frame>any relapse (max 5 years)</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale</measure>
    <time_frame>Inclusion</time_frame>
    <description>Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale</measure>
    <time_frame>6 Months</time_frame>
    <description>Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale</measure>
    <time_frame>1 year</time_frame>
    <description>Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale</measure>
    <time_frame>18 months</time_frame>
    <description>Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale</measure>
    <time_frame>2 years</time_frame>
    <description>Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale</measure>
    <time_frame>2.5 years</time_frame>
    <description>Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale</measure>
    <time_frame>3 years</time_frame>
    <description>Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale</measure>
    <time_frame>3.5 years</time_frame>
    <description>Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale</measure>
    <time_frame>4 years</time_frame>
    <description>Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale</measure>
    <time_frame>4.5 years</time_frame>
    <description>Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale</measure>
    <time_frame>5 years</time_frame>
    <description>Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale</measure>
    <time_frame>Any relapse (Maximum 5 years)</time_frame>
    <description>Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness</measure>
    <time_frame>Inclusion</time_frame>
    <description>assessed by Optical Coherence Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness</measure>
    <time_frame>6 Months</time_frame>
    <description>assessed by Optical Coherence Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness</measure>
    <time_frame>1 Year</time_frame>
    <description>assessed by Optical Coherence Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness</measure>
    <time_frame>18 Months</time_frame>
    <description>assessed by Optical Coherence Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness</measure>
    <time_frame>2 years</time_frame>
    <description>assessed by Optical Coherence Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness</measure>
    <time_frame>3 Years</time_frame>
    <description>assessed by Optical Coherence Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness</measure>
    <time_frame>4 Years</time_frame>
    <description>assessed by Optical Coherence Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness</measure>
    <time_frame>5 Years</time_frame>
    <description>assessed by Optical Coherence Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness</measure>
    <time_frame>Any relapse (maximum 5 Years)</time_frame>
    <description>assessed by Optical Coherence Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gadolinium-enhanced lesions</measure>
    <time_frame>Inclusion</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gadolinium-enhanced lesions</measure>
    <time_frame>6 Months</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gadolinium-enhanced lesions</measure>
    <time_frame>1 Year</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gadolinium-enhanced lesions</measure>
    <time_frame>2 years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gadolinium-enhanced lesions</measure>
    <time_frame>3 Years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gadolinium-enhanced lesions</measure>
    <time_frame>4 Years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gadolinium-enhanced lesions</measure>
    <time_frame>5 Years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gadolinium-enhanced lesions</measure>
    <time_frame>Any relapse (Maximum 5 Years)</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T2 lesion volume,</measure>
    <time_frame>Inclusion</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T2 lesion volume,</measure>
    <time_frame>6 Months</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T2 lesion volume,</measure>
    <time_frame>1 Year</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T2 lesion volume,</measure>
    <time_frame>2 years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T2 lesion volume,</measure>
    <time_frame>3 Years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T2 lesion volume,</measure>
    <time_frame>4 Years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T2 lesion volume,</measure>
    <time_frame>5 years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T2 lesion volume,</measure>
    <time_frame>Any relapse (maximum 5 years)</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grey matter atrophy</measure>
    <time_frame>Inclusion</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grey matter atrophy</measure>
    <time_frame>6 Months</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grey matter atrophy</measure>
    <time_frame>1 Year</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grey matter atrophy</measure>
    <time_frame>2 years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grey matter atrophy</measure>
    <time_frame>3 Years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grey matter atrophy</measure>
    <time_frame>4 Years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grey matter atrophy</measure>
    <time_frame>5 Years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grey matter atrophy</measure>
    <time_frame>Any relapse (maximum 5 Years)</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White matter atrophy</measure>
    <time_frame>Inclusion</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White matter atrophy</measure>
    <time_frame>6 Months</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White matter atrophy</measure>
    <time_frame>1 Year</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White matter atrophy</measure>
    <time_frame>2 years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White matter atrophy</measure>
    <time_frame>3 Years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White matter atrophy</measure>
    <time_frame>4 Years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White matter atrophy</measure>
    <time_frame>5 years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White matter atrophy</measure>
    <time_frame>Any relapse (maximum 5 years)</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thalamic atrophy</measure>
    <time_frame>Inclusion</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thalamic atrophy</measure>
    <time_frame>6 Months</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thalamic atrophy</measure>
    <time_frame>1 Year</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thalamic atrophy</measure>
    <time_frame>2 years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thalamic atrophy</measure>
    <time_frame>3 Years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thalamic atrophy</measure>
    <time_frame>4 Years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thalamic atrophy</measure>
    <time_frame>5 years</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thalamic atrophy</measure>
    <time_frame>Any relapse (maximum 5 years)</time_frame>
    <description>assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease modifying drugs classification</measure>
    <time_frame>Inclusion</time_frame>
    <description>Drug class (1st, 2nd or 3rd line)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease modifying drugs classification</measure>
    <time_frame>until end of study (5 years)</time_frame>
    <description>Drug class (1st, 2nd or 3rd line)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum NfL levels</measure>
    <time_frame>6 Months</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum NfL levels</measure>
    <time_frame>2 years</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum NfL levels</measure>
    <time_frame>3 years</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum NfL levels</measure>
    <time_frame>4 years</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum NfL levels</measure>
    <time_frame>5 years</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum NfL levels</measure>
    <time_frame>Any relapse (maximum 5 years)</time_frame>
    <description>pg/mL; measured by digital ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Functional Composite</measure>
    <time_frame>Inclusion</time_frame>
    <description>21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Functional Composite</measure>
    <time_frame>6 Months</time_frame>
    <description>21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Functional Composite</measure>
    <time_frame>1 Year</time_frame>
    <description>21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Functional Composite</measure>
    <time_frame>2 years</time_frame>
    <description>21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Functional Composite</measure>
    <time_frame>3 years</time_frame>
    <description>21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Functional Composite</measure>
    <time_frame>4 years</time_frame>
    <description>21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Functional Composite</measure>
    <time_frame>5 years</time_frame>
    <description>21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Functional Composite</measure>
    <time_frame>Any relapse (maximum 5 years)</time_frame>
    <description>21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to walk 100 meters</measure>
    <time_frame>Inclusion</time_frame>
    <description>Seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to walk 100 meters</measure>
    <time_frame>6 Months</time_frame>
    <description>Seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to walk 100 meters</measure>
    <time_frame>1 Year</time_frame>
    <description>Seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to walk 100 meters</measure>
    <time_frame>2 years</time_frame>
    <description>Seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to walk 100 meters</measure>
    <time_frame>3 years</time_frame>
    <description>Seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to walk 100 meters</measure>
    <time_frame>4 years</time_frame>
    <description>Seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to walk 100 meters</measure>
    <time_frame>5 years</time_frame>
    <description>Seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to walk 100 meters</measure>
    <time_frame>Any relapse (maximum 5 years)</time_frame>
    <description>Seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Minute walking distance</measure>
    <time_frame>Inclusion</time_frame>
    <description>Meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Minute walking distance</measure>
    <time_frame>6 Months</time_frame>
    <description>Meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Minute walking distance</measure>
    <time_frame>1 Year</time_frame>
    <description>Meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Minute walking distance</measure>
    <time_frame>2 years</time_frame>
    <description>Meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Minute walking distance</measure>
    <time_frame>3 years</time_frame>
    <description>Meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Minute walking distance</measure>
    <time_frame>4 years</time_frame>
    <description>Meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Minute walking distance</measure>
    <time_frame>5 years</time_frame>
    <description>Meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Minute walking distance</measure>
    <time_frame>Any relapse (maximum 5 years)</time_frame>
    <description>Meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Impairment</measure>
    <time_frame>Inclusion</time_frame>
    <description>Symbol Digit Modalities Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Impairment</measure>
    <time_frame>6 months</time_frame>
    <description>Symbol Digit Modalities Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Impairment</measure>
    <time_frame>1 Year</time_frame>
    <description>Symbol Digit Modalities Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Impairment</measure>
    <time_frame>2 years</time_frame>
    <description>Symbol Digit Modalities Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Impairment</measure>
    <time_frame>3 years</time_frame>
    <description>Symbol Digit Modalities Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Impairment</measure>
    <time_frame>4 years</time_frame>
    <description>Symbol Digit Modalities Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Impairment</measure>
    <time_frame>5 years</time_frame>
    <description>Symbol Digit Modalities Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Impairment</measure>
    <time_frame>Any relapse (maximum 5 years)</time_frame>
    <description>Symbol Digit Modalities Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive evaluation</measure>
    <time_frame>Inclusion</time_frame>
    <description>Brief International Cognitive Assessment for Multiple Sclerosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive evaluation</measure>
    <time_frame>6 Months</time_frame>
    <description>Brief International Cognitive Assessment for Multiple Sclerosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive evaluation</measure>
    <time_frame>1 Year</time_frame>
    <description>Brief International Cognitive Assessment for Multiple Sclerosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive evaluation</measure>
    <time_frame>2 years</time_frame>
    <description>Brief International Cognitive Assessment for Multiple Sclerosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive evaluation</measure>
    <time_frame>3 years</time_frame>
    <description>Brief International Cognitive Assessment for Multiple Sclerosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive evaluation</measure>
    <time_frame>4 years</time_frame>
    <description>Brief International Cognitive Assessment for Multiple Sclerosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive evaluation</measure>
    <time_frame>5 years</time_frame>
    <description>Brief International Cognitive Assessment for Multiple Sclerosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive evaluation</measure>
    <time_frame>Any relapse (maximum 5 years)</time_frame>
    <description>Brief International Cognitive Assessment for Multiple Sclerosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Inclusion</time_frame>
    <description>EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>6 Months</time_frame>
    <description>EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>1 Year</time_frame>
    <description>EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>3 years</time_frame>
    <description>EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>4 years</time_frame>
    <description>EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Any relapse (maximum 5 years)</time_frame>
    <description>EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of MS on daily life</measure>
    <time_frame>Inclusion</time_frame>
    <description>Multiple Sclerosis Impact Scale (MSIS-29)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of MS on daily life</measure>
    <time_frame>6 Months</time_frame>
    <description>Multiple Sclerosis Impact Scale (MSIS-29)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of MS on daily life</measure>
    <time_frame>1 Year</time_frame>
    <description>Multiple Sclerosis Impact Scale (MSIS-29)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of MS on daily life</measure>
    <time_frame>2 years</time_frame>
    <description>Multiple Sclerosis Impact Scale (MSIS-29)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of MS on daily life</measure>
    <time_frame>3 years</time_frame>
    <description>Multiple Sclerosis Impact Scale (MSIS-29)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of MS on daily life</measure>
    <time_frame>4 years</time_frame>
    <description>Multiple Sclerosis Impact Scale (MSIS-29)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of MS on daily life</measure>
    <time_frame>5 years</time_frame>
    <description>Multiple Sclerosis Impact Scale (MSIS-29)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of MS on daily life</measure>
    <time_frame>Any relapse (maximum 5 years)</time_frame>
    <description>Multiple Sclerosis Impact Scale (MSIS-29)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>Inclusion</time_frame>
    <description>Modified Fatigue Impact Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>6 Months</time_frame>
    <description>Modified Fatigue Impact Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>1 Year</time_frame>
    <description>Modified Fatigue Impact Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>2 years</time_frame>
    <description>Modified Fatigue Impact Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>3 years</time_frame>
    <description>Modified Fatigue Impact Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>4 years</time_frame>
    <description>Modified Fatigue Impact Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>5 years</time_frame>
    <description>Modified Fatigue Impact Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>Any relapse (maximum 5 years)</time_frame>
    <description>Modified Fatigue Impact Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Any relapse (maximum 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low contrast visual acuity</measure>
    <time_frame>Inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low contrast visual acuity</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low contrast visual acuity</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low contrast visual acuity</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low contrast visual acuity</measure>
    <time_frame>3 years,</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low contrast visual acuity</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low contrast visual acuity</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low contrast visual acuity</measure>
    <time_frame>Any relapse (maximum 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse description</measure>
    <time_frame>At relapse (maximum 5 years)</time_frame>
    <description>monofocal, plurifocal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new lesions</measure>
    <time_frame>At relapse (maximum 5 years)</time_frame>
    <description>Measured by MRI</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>MS patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Brain MRI</intervention_name>
    <description>Axial DWI with ADC card&#xD;
Axial 2D TSE T2/DP or 3DT2&#xD;
Gadolinium injection (0.1 mmol/kg)&#xD;
3D Fluid-attenuated inversion recovery&#xD;
3D T1 with Gadolinium injection.</description>
    <arm_group_label>MS patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Spinal Cord MRI</intervention_name>
    <description>Sagittal T2 Sagittal T1 with Gadolinium injection</description>
    <arm_group_label>MS patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Retinal imaging</intervention_name>
    <description>spectral-domain high definition optical coherence tomography</description>
    <arm_group_label>MS patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is composed of consecutive adult patients, of both sexes, recruited&#xD;
        during consultations for a CIS, RRMS or progressive MS at the Neurology department of Nîmes&#xD;
        University Hospital (CHU). The patients recruited will have an EDSS score comprised between&#xD;
        0 - 7.0.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient has been correctly informed.&#xD;
&#xD;
          -  The patient must have given their informed and signed consent.&#xD;
&#xD;
          -  The patient must be insured or beneficiary of a health insurance plan.&#xD;
&#xD;
          -  The patient is at least (≥)18 years old.&#xD;
&#xD;
          -  The patient has experienced a CIS, has currently a RRMS or progressive MS with:&#xD;
&#xD;
               -  Less than 10 years of disease duration;&#xD;
&#xD;
               -  With or without DMD;&#xD;
&#xD;
               -  EDSS score 0 - 7.0.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient is in an exclusion period determined by a previous study.&#xD;
&#xD;
          -  The patient is under judicial protection.&#xD;
&#xD;
          -  The patient refuses to sign the consent.&#xD;
&#xD;
          -  It is impossible to correctly inform the patient (Inability to understand the study,&#xD;
             language problem).&#xD;
&#xD;
          -  The patient is pregnant or breast-feeding.&#xD;
&#xD;
          -  Patient has a bilateral optic neuritis or other significant ophthalmological&#xD;
             antecedent.&#xD;
&#xD;
          -  Patient with MRI contra-indications.&#xD;
&#xD;
          -  patient has a contraindication to gadolinium injection&#xD;
&#xD;
          -  The patient has bilateral optic neuritis or other significant ophthalmological&#xD;
             antecedent&#xD;
&#xD;
          -  Patient is having a relapse or has had a relapse in the last 3 months&#xD;
&#xD;
          -  The patient has a severe psychiatric illness&#xD;
&#xD;
          -  The patient has severe chronic alcoholism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Thouvenot</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Thouvenot</last_name>
    <phone>+33.(0)4.66.68.32.61</phone>
    <email>eric.thouvenot@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Thouvenot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc Jeanjean, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

